Relief Therapeutics Holding SA (RLFTF)
OTCMKTS · Delayed Price · Currency is USD
3.600
+0.010 (0.27%)
Oct 24, 2025, 2:48 PM EDT
RLFTF Revenue
Relief Therapeutics Holding had revenue of 1.22M CHF in the half year ending June 30, 2025, a decrease of -57.10%. This brings the company's revenue in the last twelve months to 4.05M, down -52.81% year-over-year. In the year 2024, Relief Therapeutics Holding had annual revenue of 8.42M with 39.52% growth.
Revenue (ttm)
4.05M CHF
Revenue Growth
-52.81%
P/S Ratio
8.76
Revenue / Employee
130.77K CHF
Employees
31
Market Cap
44.63M USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8.42M | 2.38M | 39.52% |
| Dec 31, 2023 | 6.03M | -48.00K | -0.79% |
| Dec 31, 2022 | 6.08M | 2.76M | 83.11% |
| Dec 31, 2021 | 3.32M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| Nuo Therapeutics | 1.95M |
| Northwest Biotherapeutics | 1.09M |
Relief Therapeutics Holding News
- 2 months ago - Relief Therapeutics Publishes 2025 Half-Year Report - Accesswire
- 2 months ago - Relief Therapeutics Advances Publication of 2025 Half-Year Report - Accesswire
- 3 months ago - Relief Therapeutics reports proposed business combination with NeuroX - Seeking Alpha
- 3 months ago - Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze - Accesswire
- 4 months ago - Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011 - Accesswire
- 4 months ago - Relief Therapeutics Announces Results of Annual General Meeting - Accesswire
- 5 months ago - Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011 - Accesswire
- 5 months ago - Relief Therapeutics Publishes 2025 Annual General Meeting Agenda - Accesswire